These data led to a US multi-center phase III clinical trial in patients with advanced HR-positive breast cancer, but the trial did not meet the endpoint in AI-resistant HR-positive/HER2-negative breast cancer when treated with exemestane plus entinostat [142]. Here, ERBB2 is linked to breast carcinoma.